H. Lundbeck A/S (Lundbeck), a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, announced that the last patient has been randomized ...

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients ...

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients ...

Device‑agnostic ePRO that is BYOD (bring your own device) with email/SMS reminders, patient portals, and unified reporting across EDC and eDiaries AUSTIN, TX / ACCESS Newswire / March 10, 2026 / ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

The recreational drugs cannabis, cocaine and amphetamines significantly increase the risk of stroke—including among younger ...

By Pooja Toshniwal Paharia A new perspective argues that understanding the lifelong web of environmental exposures, from early childhood to older age, could unlock more precise strategies for ...

An incredible evolution of an already great spin-off series.

Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE ...

The recent announcement that Slay the Spire 2 would include four-player co-op support came as quite a surprise to me. This ...

Metabolic dysfunction, rather than steatotic liver disease (SLD), seems to be the main driver of chronic kidney disease (CKD) risk.

Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...